Research Analysts Issue Forecasts for UTHR FY2024 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of United Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of $25.09 for the year, down from their previous estimate of $25.94. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q1 2025 earnings at $6.95 EPS, Q2 2025 earnings at $7.31 EPS, Q3 2025 earnings at $7.81 EPS, FY2025 earnings at $29.77 EPS, FY2026 earnings at $31.02 EPS, FY2027 earnings at $30.53 EPS and FY2028 earnings at $32.83 EPS.

Several other research firms have also commented on UTHR. The Goldman Sachs Group lifted their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Argus lifted their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright lifted their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $382.08.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $370.44 on Wednesday. United Therapeutics has a fifty-two week low of $211.61 and a fifty-two week high of $417.82. The firm has a market capitalization of $16.54 billion, a PE ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. The stock’s 50-day simple moving average is $361.91 and its 200-day simple moving average is $358.41.

Insider Buying and Selling at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 121,864 shares of company stock worth $44,516,965. 11.90% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

A number of institutional investors have recently modified their holdings of UTHR. Wealthfront Advisers LLC boosted its position in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. Norges Bank purchased a new stake in United Therapeutics during the fourth quarter worth $151,764,000. FMR LLC boosted its position in United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after purchasing an additional 393,777 shares in the last quarter. World Investment Advisors LLC purchased a new stake in United Therapeutics during the third quarter worth $139,206,000. Finally, Thrivent Financial for Lutherans boosted its position in United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock worth $72,085,000 after purchasing an additional 189,967 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.